Skip to main
MLYS
MLYS logo

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics, Inc. is gaining positive market sentiment due to the demonstrated efficacy of its product candidate, lorundrostat, which has achieved significant blood pressure reductions of 8-12 mmHg in patients with uncontrolled and resistant hypertension. The company's pivotal trial results highlight a robust placebo-adjusted reduction of 9.1 mmHg at 6 weeks and 11.7 mmHg at 12 weeks, with a favorable hyperkalemia rate, suggesting a strong safety profile that could enhance adoption among healthcare providers. Furthermore, the anticipated clinical success of lorundrostat supports its potential as a daily-use treatment option, positioning Mineralys favorably in a market with significant unmet needs in hypertension management.

Bears say

Mineralys Therapeutics Inc reported a significant net loss of $48.9 million for the fourth quarter of 2024 and $177.8 million for the entire year, indicating a concerning financial trajectory with losses per share reaching $0.98 and $3.66 respectively. The company's outlook is shadowed by crucial risks, including the potential failure of its drug candidates to meet commercial revenue estimates, which could be impacted by factors such as market size, penetration rates, and pricing strategies. Furthermore, the company's ability to secure adequate capital resources for ongoing operations and to advance its development and commercialization programs remains a critical concern, potentially jeopardizing its long-term viability.

MLYS has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 8 analysts, MLYS has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.